Skyline Diagnostics B.V. announced today the successful closure of its Series A financing round. The investors syndicate participating in this financing is formed by the Erasmus MC Biomedical Fund and LSP (Life Sciences Partners). Skyline Diagnostics is a spin-off company from the Erasmus University Medical Center in Rotterdam. The company develops and commercializes diagnostic tools for cancer using microarray technology. The diagnostic device furnishes a genomic fingerprint of the tumor that permits a precise diagnosis and a predictive assessment of the individual’s prognosis. The company currently has three products in its development pipeline: biochips for acute myeloid leukemia, brain tumors and multiple myeloma (Kahler’s disease). Dr. Henk Viëtor, CEO of Skyline Diagnostics: “We very pleased to have two experienced venture capital investors like LSP and the Erasmus MC Biomedical Fund investing in our company. This will enable Skyline to fulfill its ambitions to take the next essential steps in bringing its first product, the AML Biochip, to the market. Acute myeloid leukemia (AML) is the most common form of leukemia. This product will provide clinicians new insights in the prognosis and course of the disease.”
